Washington, D.C. — The Supreme Court has temporarily allowed continued access to the abortion pill mifepristone by mail, pausing a lower court ruling that would have restricted distribution nationwide.
Justice Samuel Alito issued an administrative stay that keeps telehealth prescriptions and mail delivery in place while the court reviews emergency appeals from drugmakers. The pause is expected to remain in effect until at least May 11, when justices may decide whether to extend or lift the order.
The case stems from a lawsuit led by Louisiana challenging federal rules that allow mifepristone to be prescribed without in-person visits. State officials argued the policy conflicts with state abortion restrictions and creates additional public costs.
Medication abortion accounts for more than 60% of abortions in the United States, making the outcome of the case significant for access nationwide. Drug manufacturers Danco Laboratories and GenBioPro have intervened to defend the current regulations.
The dispute follows broader legal battles after the 2022 decision overturning Roe v. Wade, which allowed states to enact stricter abortion laws. Federal regulators are also reviewing the drug’s safety guidelines as litigation continues.
The court’s temporary action leaves existing access unchanged while legal challenges proceed.
Sources:
Discover more from News Facts Network
Subscribe to get the latest posts sent to your email.
